The FDA has approved Yupelri, a once-daily inhalable solution for the maintenance treatment of patients with COPD.

Yupelri belongs to a class of drugs called long-acting muscarinic antagonists (LAMA), with the existing treatment options primarily being hand-held devices such as Boehringer Ingelheim’s Spiriva.

The treatment is expected to be made available in the United States before the end of the year, Theravance and Mylan said in a statement.